Key Takeaways ANGO posted strong fiscal Q2 2026 results, with revenue up 8.8% year over year to $79.4 million.ANGO's NanoKnife revenue rose 22.2% as prostate cancer procedures hit record volumes.ANGO's Auryon franchise grew 18.6%, supporting a Med Tech mix shift and gross margin expansion.AngioDynamics (ANGO) has been gaining from its solid prospects with NanoKnife and an increased focus on cancer treatment markets. The optimism, led by a solid second-quarter fiscal 2026 performance, positive ongoing studie ...

Karim Boussebaa Appointed Chief Executive Officer of Guerbet Villepinte, January 28, 2026: Guerbet (FR0000032526 GBT), a global specialist in contrast agents and solutions for medical imaging, announces the appointment of Mr. Karim Boussebaa as Chief Executive Officer of the Group. Meeting today, Guerbet’s Board of Directors, following the recommendation of the Nominations and Compensation Committee, has decided to appoint Mr. Karim Boussebaa as Chief Executive Officer. This appointment will take effect on ...

Core Insights - The U.S. FDA has granted 510(k) clearance for Becton, Dickinson and Company's new breast biopsy system, the EnCor EnCompass, expected to launch in early 2026 [1][2] Product Overview - The EnCor EnCompass system features advanced capabilities such as high and low vacuum strengths, 360-degree sampling ability, and customizable probes for different lesion types [2] Market Valuation and Performance - Becton, Dickinson maintains a market capitalization of $59.10 billion, with a 52-week stock price range of $162.29 to $251.99 [3] - The stock is currently up 0.25% at $207.90, aligning with broader market gains, as the S&P 500 is up 0.50% [3][10] Earnings Forecast and Analyst Ratings - Analysts forecast earnings per share of $2.82, down from $3.43 in the same quarter last year, and revenue of $5.15 billion, slightly down from $5.17 billion [4] - The consensus rating among analysts is "Buy," with an average price target of $245.93, indicating the stock may be trading at a premium [4] Technical Analysis - The Relative Strength Index (RSI) is at 66.21, indicating neutral to bullish momentum [7] - The MACD shows bullish momentum with a value of 2.94, indicating the MACD line is above the signal line [7] - Key support level is at $188.50 and resistance level is at $208 [7] Momentum and Value Assessment - The Benzinga Edge score indicates a "High-Flyer" setup, with a momentum score of 35.35 confirming positive trends, but a low value score of 24.16 suggests the stock is priced for perfection [5][8] ETF Impact - Becton, Dickinson has notable weights in key ETFs, including T. Rowe Price Capital Appreciation Equity ETF (2.94%), iShares US Medical Devices ETF (4.44%), and Kovitz Core Equity ETF (4.20%) [9]

Core Viewpoint - Inspira Technologies is positioning itself to enter the multi-billion dollar liquid biopsy diagnostics market through a proposed acquisition and a strategic equity investment of $15 million, while ensuring protections for existing shareholders [1][2]. Equity Investment - The proposed transaction includes a $15 million equity investment at a premium to the current market capitalization, based on a pre-money valuation of $180 million, reflecting the strategic investor's assessment of the liquid biopsy technology's potential [3]. - The identity of the strategic investor will be disclosed after shareholder approval and execution of definitive agreements, with $12 million of the investment proceeds allocated to fund existing technologies [4]. Strategic Acquisition - The acquisition involves an advanced liquid biopsy diagnostics business, allowing Inspira to enter the growing liquid biopsy market with a proprietary platform designed for cancer characterization [5]. - The platform has shown high concordance with traditional tissue biopsy in clinical studies, indicating its potential to provide valuable diagnostic insights [5][6]. - The initial clinical focus of the platform is on breast cancer, with a projected global liquid biopsy market size of approximately $58 billion over the next decade [6]. Regulatory Pathway - Following the acquisition, the company plans to pursue FDA clearance for the liquid biopsy platform through the 510(k) regulatory pathway, leveraging existing regulatory precedents [7]. - An existing reimbursement code is already in place for the intended clinical use, facilitating a clear path to reimbursement upon regulatory clearance [8]. Shareholder Protection Framework - The transaction includes a shareholder protection framework to preserve the economic upside of existing technologies for current shareholders while allowing participation in the growth potential of the liquid biopsy platform [9]. - Existing shareholders are expected to receive contingent value rights, ensuring that future realizations of value from respiratory technology assets are allocated exclusively to them [9]. Company Overview - Inspira Technologies specializes in advanced respiratory support and real-time blood monitoring solutions, with FDA-cleared products and a growing IP portfolio [10].

国家药监局召开脑机接口医疗器械工作推进会。会议要求，要坚持安全有效为首要前提，构建标准体系，加强技术指导服务；要加强跨部门合作，联手产学研医各方，合力解决关键技术问题，完善产业链供应链；要落实企业主体责任，提升产品可靠性和整体竞争力，积极推动脑机接口器械更快更好服务临床。 ...

Core Insights - Picard Medical, Inc. successfully completed its initial public offering (IPO) on September 2, 2025, raising approximately $19.5 million in gross proceeds, which will be used to strengthen its balance sheet and accelerate research and development [4][7]. Financial Performance - Third quarter revenue reached $1.19 million, a 35% increase from the same period in 2024, driven by higher U.S. product sales and increased driver rentals [5]. - The cost of revenue declined by 15% year-over-year, resulting in a gross loss reduction of 81% to $0.13 million [5]. - Operating expenses decreased by 11% to $3.36 million, leading to a narrowed operating loss of $3.36 million compared to $3.77 million in Q3 2024 [6]. - For the nine-month period ending September 30, 2025, revenue totaled $3.93 million, an 11% increase from 2024, while the operating loss remained consistent at $10.3 million [7]. Strategic Developments - The company secured additional patent protection for its SynCardia Total Artificial Heart (STAH), reinforcing its commitment to life-saving technology [3]. - Two independent directors, Sam Van and George Ye, were appointed to the board to provide leadership and guidance as the company transitions to a public entity [3][7]. - A new patent (U.S. Patent No. 12,383,722 B2) was granted for the next-generation fully implantable SynCardia Total Artificial Heart, expanding the company's intellectual property portfolio [7]. Market Position - Picard Medical, through its subsidiary SynCardia, is the only company with commercially available total artificial heart technology for patients with end-stage heart failure, with over 2,100 implants performed globally [10].

The problem of working out exactly which sort of snake did the biting may soon be a thing of the past—and an awful lot of lives may be saved in the process https://t.co/NNi2N1ja5H ...

Core Insights - AngioDynamics, Inc. will participate in the UBS Global Healthcare Conference on November 10, 2025, with CEO Jim Clemmer and CFO Stephen Trowbridge presenting [1] - The company's NanoKnife System has been recognized as one of TIME's 2025 Best Inventions, highlighting its innovative impact in medical technology [6] - AngioDynamics reported a net sales figure of $75.7 million for the first quarter of fiscal year 2026, reflecting a year-over-year growth of 26.1% in the medical technology sector [7] Company Overview - AngioDynamics is a medical technology company focused on restoring healthy blood flow, expanding cancer treatment options, and improving patient quality of life [3][6] - The company’s innovative technologies are utilized by physicians in rapidly growing healthcare markets to address unmet patient needs [3] Financial Performance - For the first quarter of fiscal year 2026, which ended on August 31, 2025, AngioDynamics achieved net sales of $75.7 million, indicating strong growth in the medical technology sector [7]

Core Viewpoint - NVE Corporation's shares have experienced a 1.5% decline following the release of its second-quarter fiscal 2026 results, despite a 9.7% increase over the past month, indicating investor optimism about future growth prospects despite current revenue challenges [1] Earnings & Revenue Performance - Total revenues for the quarter ended September 30, 2025, were $6.35 million, a 6% decrease from $6.76 million in the prior year, primarily due to a 68% drop in contract R&D revenues, partially offset by a 1% increase in product sales [2] - For the first half of fiscal 2026, total revenues decreased 8% year over year to $12.45 million, with net income down 15% to $6.89 million, or $1.42 per diluted share [3] Operating Trends & Other Key Business Metrics - Gross profit for the quarter declined 14% to $4.97 million, resulting in a gross margin of 78%, down from 86% the previous year due to a less profitable product mix and increased distributor sales [4] - Operating expenses fell 7%, driven by a 23% decrease in SG&A costs, while R&D spending rose by 3% [5] Management Commentary - The CEO highlighted a 4% sequential revenue increase driven by strong growth in distributor and non-defense sales, despite a decline in defense-related business [7] - The company is shifting focus towards medical devices, industrial automation, and robotics markets, leveraging its spintronic sensors and couplers [8] Factors Influencing Performance - Revenue decline was mainly due to cyclical weakness in contract R&D, with a 21% rise in non-defense product sales partially offsetting a 64% decline in defense sales [11] - The lower gross margin was attributed to a shift in sales mix and a 45% year-over-year increase in the cost of sales due to heightened manufacturing activity [12] Outlook - Management is optimistic about continued growth in the December quarter and the second half of fiscal 2026, citing a healthy sales pipeline and favorable tax credits [14] - The company plans to spend an additional $1-$1.5 million on capital expenditures for production expansion [14] Other Developments - The board declared a quarterly cash dividend of $1 per share, payable on November 28, 2025, and reported the completion of new manufacturing equipment installation [16]

Core Insights - Exact Sciences Corporation (EXAS) is positioned for growth due to the momentum in its Cologuard and Oncotype DX tests, with ongoing investments in innovative cancer diagnostic solutions [1][4][9] - The company has a market capitalization of $10.20 billion and an estimated long-term earnings growth rate of 30.1%, outperforming the industry average of 21% [3] - Exact Sciences aims for 15% compounded revenue growth and over 20% adjusted EBITDA margins, with expected annual savings of more than $150 million by 2026 [5][9] Growth Drivers - Cologuard's growth is supported by rescreens, care gap programs, and improved commercial execution, with a focus on making it the standard of care [4] - Oncotype DX is experiencing strong international uptake, with a significant opportunity for growth as 70% of eligible patients outside the U.S. are not currently tested [4] - The launch of new products, such as Oncodetect and Cologuard Plus, enhances the company's offerings and addresses market needs [6][7][10] Operational Challenges - The company faces macroeconomic pressures, including high-interest rates and limited access to capital markets, which could impact profitability [13] - A competitive landscape in the colorectal cancer screening market poses risks, with competitors having greater resources and capabilities [14] Financial Performance - In the past year, EXAS stock has declined by 13.6%, while the S&P 500 has risen by 18.9% [2] - The Zacks Consensus Estimate for Exact Sciences' 2025 earnings has increased by 13.8% to 33 cents, with revenues projected to reach $3.16 billion, reflecting a 14.4% increase from 2023 [15]